2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Arylsulfatase D is a prognostic biomarker that promotes glioma cells progression through JAK2/STAT3 pathway and M2 macrophage infiltration

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Arylsulfatase D (ARSD) belongs to the sulfatase family and plays a crucial role in maintaining the proper structure of bone and cartilage matrix. Although several researches have revealed the functions of ARSD in tumor progression, the prognostic value of ARSD in glioma and the related mechanisms have not been fully investigated.

          Methods

          We performed a pan-cancer analysis of ARSD, and investigated the relationship between expression of ARSD and overall survival (OS) in multiple glioma datasets. ROC curves and nomograms were created to investigate the predictive capacity of ARSD. Immune and analysis were conducted to investigate the mechanisms underlying the roles of ARSD in glioma. Glioma tissue samples were collected to verify the expression of ARSD in glioma, while the functions of ARSD were explored using cell experiment. M2 macrophage infiltration assay was used to determine the relation between ARSD and tumor immune microenvironment.

          Results

          Survival analysis indicated that individuals with high ARSD expression in glioma had a shorter survival time. Cox analysis showed that ARSD had a good ability for predicting prognosis in glioma. Immune analysis suggested that ARSD could regulate immune cell infiltration and affect the Cancer-Immunity Cycle to create an immunosuppressive environment. Combined with cell experiment and bioinformatic analysis, we found that ARSD can promote glioma progression through regulation of JAK2/STAT3 pathway and M2 macrophage infiltration.

          Conclusion

          Our study found that ARSD can promote glioma development by regulating immune microenvironment and JAK2/STAT3 signaling pathway, which provided a potential therapy target for glioma treatment.

          Related collections

          Most cited references30

          • Record: found
          • Abstract: found
          • Article: not found

          clusterProfiler: an R package for comparing biological themes among gene clusters.

          Increasing quantitative data generated from transcriptomics and proteomics require integrative strategies for analysis. Here, we present an R package, clusterProfiler that automates the process of biological-term classification and the enrichment analysis of gene clusters. The analysis module and visualization module were combined into a reusable workflow. Currently, clusterProfiler supports three species, including humans, mice, and yeast. Methods provided in this package can be easily extended to other species and ontologies. The clusterProfiler package is released under Artistic-2.0 License within Bioconductor project. The source code and vignette are freely available at http://bioconductor.org/packages/release/bioc/html/clusterProfiler.html.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            GSVA: gene set variation analysis for microarray and RNA-Seq data

            Background Gene set enrichment (GSE) analysis is a popular framework for condensing information from gene expression profiles into a pathway or signature summary. The strengths of this approach over single gene analysis include noise and dimension reduction, as well as greater biological interpretability. As molecular profiling experiments move beyond simple case-control studies, robust and flexible GSE methodologies are needed that can model pathway activity within highly heterogeneous data sets. Results To address this challenge, we introduce Gene Set Variation Analysis (GSVA), a GSE method that estimates variation of pathway activity over a sample population in an unsupervised manner. We demonstrate the robustness of GSVA in a comparison with current state of the art sample-wise enrichment methods. Further, we provide examples of its utility in differential pathway activity and survival analysis. Lastly, we show how GSVA works analogously with data from both microarray and RNA-seq experiments. Conclusions GSVA provides increased power to detect subtle pathway activity changes over a sample population in comparison to corresponding methods. While GSE methods are generally regarded as end points of a bioinformatic analysis, GSVA constitutes a starting point to build pathway-centric models of biology. Moreover, GSVA contributes to the current need of GSE methods for RNA-seq data. GSVA is an open source software package for R which forms part of the Bioconductor project and can be downloaded at http://www.bioconductor.org.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

              The cBio Cancer Genomics Portal (http://cbioportal.org) is an open-access resource for interactive exploration of multidimensional cancer genomics data sets, currently providing access to data from more than 5,000 tumor samples from 20 cancer studies. The cBio Cancer Genomics Portal significantly lowers the barriers between complex genomic data and cancer researchers who want rapid, intuitive, and high-quality access to molecular profiles and clinical attributes from large-scale cancer genomics projects and empowers researchers to translate these rich data sets into biologic insights and clinical applications. © 2012 AACR.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Oncol
                Front Oncol
                Front. Oncol.
                Frontiers in Oncology
                Frontiers Media S.A.
                2234-943X
                12 September 2023
                2023
                : 13
                : 1228426
                Affiliations
                [1] 1 Department of Neurosurgery, The Second Hospital of Hebei Medical University , Shijiazhuang, Hebei, China
                [2] 2 Spine Center, Sanbo Brain Hospital, Capital Medical University , Beijing, China
                [3] 3 Department of Neurosurgery, The Fourth Hospital of Hebei Medical University , Shijiazhuang, Hebei, China
                [4] 4 Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing, China
                Author notes

                Edited by: Qianghu Wang, Nanjing University, China

                Reviewed by: Braden C. McFarland, University of Alabama at Birmingham, United States; Tao Jiang, Zhejiang Chinese Medical University, China

                *Correspondence: Zongmao Zhao, zzm692017@ 123456sina.com

                †These authors have contributed equally to this work

                Article
                10.3389/fonc.2023.1228426
                10521731
                37766864
                bbe21b96-3c5e-4661-b208-10e5bd89cc0f
                Copyright © 2023 Song, Zhao, Zhu, Jin, Zhang, Wang, Shen, Wang and Zhao

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 24 May 2023
                : 21 August 2023
                Page count
                Figures: 10, Tables: 1, Equations: 0, References: 30, Pages: 15, Words: 4911
                Funding
                This research was supported by National Natural Science Foundation of China (81870984); National Key R & D Program Intergovernmental Cooperation on International Scientific and Technological Innovation of the Ministry of Science and Technology of China (2017YFE0110400); Hebei Natural Science Foundation General Project— Beijing-Tianjin-Hebei Basic Research Cooperation Project (H2018206675); Special Project for the Construction of Hebei Province International Science and Technology Cooperation Base (193977143D); 2017 Hebei Provincial Outstanding Clinical Medical Personnel Training and Basic Research Funding Project; National funded project of Hebei Provincial Excellent Clinical Medical Personnel Training and Basic Research Project in 2019. 2023 Hebei Province Introducing Foreign Intelligence Program. 2023 Government Funding for Excellence in Clinical Medicine Program.
                Categories
                Oncology
                Original Research
                Custom metadata
                Neuro-Oncology and Neurosurgical Oncology

                Oncology & Radiotherapy
                arsd,glioma,prognosis,m2 macrophages,jak2/stat3 pathway
                Oncology & Radiotherapy
                arsd, glioma, prognosis, m2 macrophages, jak2/stat3 pathway

                Comments

                Comment on this article